3 Healthcare Stocks for your watchlist – MVP, PGC and ZNT


While market volatility is taking a different turn these days and many diverse sectors are witnessing the impact. One sector that looks to be under watch is the healthcare domain. The big names like CSL, Cochlear and Ramsay seem to have their own trajectory but one sub-segment to closely watch is that of junior players. Below are 3 players under the category.

Medical Developments International Ltd.’s (ASX: MVP) stock traded around $4.5 with a daily price change of -$0.050 or a percentage change of -1.09%, as at August 02, 2018, market open. The annual dividend yield for the stock is 0.86% which is fully franked. The most recent dividend declared is 2c with dividend ex-date as March 02, 2018 and dividend pay-date as April 13, 2018. Over the past 5 years, the stock has seen a performance change of 238.69% in positive. The company recently met with the U.S. Food and Drug Administration (FDA) with regards to its Penthrox product. Primarily, FDA has put the approval for clinical program for Penthrox for sale in the USA on hold and a letter outlining outstanding issues and concerns is to be issued, as advised by the FDA. For more than 30 years in Australia and with more than 6.0 million units sold, Penthrox has been used safely and effectively.

Paragon Care Ltd (ASX: PGC) is another healthcare stock that was trading at a market price of $0.80 with a daily price change of -$0.005 and a percentage change of -0.621%, as at August 02, 2018, market open. The stock has an annual dividend yield of 3.75% which is fully franked, and this is better than many other healthcare stocks. The most recent dividend declared was of 1.1c with dividend ex-date as March 15, 2018 and dividend pay date as April 12, 2018. The company’s most recent acquisition was of REM Systems Limited for a transaction value of $7.53 million which was announced on June 08, 2018. The company recently appointed Ms. Melanie Leydin as joint company secretary.

Zenitas Healthcare Limited (ASX: ZNT) was trading at a market price of $1.135 (as at August 02, 2018, post market open), and the stock has remained flat over the past 12 months. The annual dividend yield of the stock is 0.9%. The company has entered into binding agreements to acquire 100% of the shares in Australian Home Care Services (AHCS), which is a leading home care provider in Victoria and New South Wales; and Beleura Health Solutions (Beleura), an operator of two Allied Health clinics on the Mornington Peninsula in Victoria. The company has recently announced the acquisition of Australian Home Care Services, while the price was of $4 million for 100% AHCS funded from the Company’s existing cash reserve. The company’s FY19 revenue and EBITDA is expected to be $38 million and $2 million, respectively. Meanwhile, Zenitas is making changes to its board with appointment of a new Chief Operating Officer. The group witnessed a 4.6% rise on August 02, 2018, early trading and is gaining traction lately.

[pluginops_form template_id=’23834′ ]

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report